Benoît Hébert

Benoît Hébert has worked for more than 25 years in private and public biopharmaceutical companies, occupying various executive management roles with operational responsibilities spanning licensing and M&A, to technical operational areas including manufacturing and regulatory affairs.

He is presently the CEO of teräcero Canada inc., a startup pharmaceutical company that will be fully integrated from R&D, manufacturing, and commercial operations.

He built a successful consulting practice which led him to join Pediapharm upon its inception where his responsibilities extended beyond deal making to the management of other operational areas as diverse as regulatory affairs, market access, medical affairs, quality assurance, manufacturing, and supply chain management. During his 10-year tenure, he was directly responsible for all licensing and acquisition transactions, and for the regulatory approval of four new drugs, including one NCE, and medical devices.

He previously assumed global business development responsibilities at Axcan Pharma where he led international licensing transactions, participated actively in product acquisitions exceeding 100M$, managed international product development alliances and global supplier relationships.

In addition to his MBA in Management of Bio-industries from the Université du Québec à Montréal, Benoît received a M.Sc. in Immunology and a Ph.D. in Virology from the Institut Armand-Frappier.

He is a former President and Director of the Canadian Healthcare Licensing Association (CHLA), and a Director of the Fondation Armand-Frappier.

As a recognition of impact in the field of pharmaceutical licensing, Benoît was inducted in the CHLA’s Business Development Hall of Fame in 2017.